Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study
- PMID: 2682692
- DOI: 10.1055/s-2007-1014603
Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study
Abstract
The therapeutic efficacy of lithium added to tricyclic antidepressants (TCA) or related thymoleptics was investigated in 27 endogenous depressive patients responding unsatisfactorily to these drugs alone. All patients received lithium during two weeks, however, with a delay of one week in 13 of them, the attribution to active treatment or placebo for the first seven days being double-blind. A statistically significant improvement compared to placebo occurred after lithium addition. The results of the double-blind part of the study as well as the observations during the total two-week period suggest that endogenous depression failing to respond to thymoleptic drug treatment can be improved within a short time by the co-administration of the two treatments in the indicated sequence. However, the proportion of patients improved and the rapidity of improvement noted in this study were less favorable than reported by the investigators who discovered the therapeutic principle.
Similar articles
-
Lithium addition in endogenous depressions resistant to tricyclic antidepressants or related drugs: relation to the status of the pituitary-thyroid axis.Pharmacopsychiatry. 1994 Sep;27(5):198-201. doi: 10.1055/s-2007-1014304. Pharmacopsychiatry. 1994. PMID: 7838890 Clinical Trial.
-
Efficacy of bupropion in tricyclic-resistant or intolerant patients.J Clin Psychiatry. 1983 May;44(5 Pt 2):148-52. J Clin Psychiatry. 1983. PMID: 6406447 Clinical Trial.
-
Treatment of depressions resistant to tricyclic antidepressants, related drugs or MAO-inhibitors by lithium addition: review of the literature.Pharmacopsychiatry. 1989 Sep;22(5):174-82. doi: 10.1055/s-2007-1014602. Pharmacopsychiatry. 1989. PMID: 2682691 Review.
-
On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression--a placebo-controlled double-blind trial with doxepin.Pharmacopsychiatry. 1997 Mar;30(2):62-9. doi: 10.1055/s-2007-979484. Pharmacopsychiatry. 1997. PMID: 9131726 Clinical Trial.
-
Treatment of depression in bipolar disorder: new directions for research.J Clin Psychopharmacol. 1993 Dec;13(6):397-408. J Clin Psychopharmacol. 1993. PMID: 8120153 Review.
Cited by
-
Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.J Affect Disord. 2022 Apr 1;302:385-400. doi: 10.1016/j.jad.2021.12.134. Epub 2022 Jan 2. J Affect Disord. 2022. PMID: 34986373 Free PMC article.
-
[Twenty-five years of lithium augmentation].Nervenarzt. 2007 Nov;78(11):1237-47. doi: 10.1007/s00115-007-2273-5. Nervenarzt. 2007. PMID: 17458527 Review. German.
-
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.J Psychopharmacol. 2021 Aug;35(8):890-900. doi: 10.1177/02698811211013579. Epub 2021 Jul 9. J Psychopharmacol. 2021. PMID: 34238049 Free PMC article.
-
[Therapy resistance to antidepressants. Definition, prevalence, predictors, and interventional possibilities].Nervenarzt. 2004 May;75(5):499-515; quiz 516-7. doi: 10.1007/s00115-004-1728-1. Nervenarzt. 2004. PMID: 15127144 Review. German.
-
Role of lithium augmentation in the management of major depressive disorder.CNS Drugs. 2014 Apr;28(4):331-42. doi: 10.1007/s40263-014-0152-8. CNS Drugs. 2014. PMID: 24590663 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources